This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric
patients with epilepsy and clinically significant anxiety will be recruited and if enrolled
will receive active treatment, involving flexible dose titration of clobazam and will be
monitored for a period of four months. The study will be monitored and overseen by the Johns
Hopkins Hospital Institutional Review Board.
Phase:
Phase 4
Details
Lead Sponsor:
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.